ZOGENIX INC (ZGNX)

Company Profile

Zogenix, Inc. is a pharmaceutical company. The company is headquartered in Emeryville, California and currently employs 218 full-time employees. The company went IPO on 2010-11-23. The firm is engaged in the development and commercialization of therapies for rare diseases. The company is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla (fenfluramine) is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. Fintepla is also under development in Japan. The firm also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal. MT1621 is in late-stage development.

Company Info

ZOGENIX INC

5959 Horton St Ste 500

Emeryville CALIFORNIA 94608

P: 15105508300.0

CEO: Stephen J. Farr

Employees: 218

Website: http://www.zogenix.com/